NEXT Financial Group Inc Sells 3,936 Shares of Sanofi (SNY)
NEXT Financial Group Inc trimmed its stake in Sanofi (NYSE:SNY) by 33.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,732 shares of the company’s stock after selling 3,936 shares during the period. NEXT Financial Group Inc’s holdings in Sanofi were worth $383,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of SNY. Parallel Advisors LLC increased its holdings in Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares during the period. YorkBridge Wealth Partners LLC boosted its position in Sanofi by 33.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after acquiring an additional 776 shares during the last quarter. Eagle Ridge Investment Management bought a new stake in Sanofi during the second quarter valued at $160,000. Bronfman E.L. Rothschild L.P. boosted its position in Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after acquiring an additional 2,098 shares during the last quarter. Finally, Toronto Dominion Bank boosted its position in Sanofi by 4.6% during the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after acquiring an additional 180 shares during the last quarter. Institutional investors and hedge funds own 9.30% of the company’s stock.
In related news, major shareholder Sanofi acquired 105,820 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were bought at an average price of $482.04 per share, with a total value of $51,009,472.80. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.00% of the stock is owned by corporate insiders.
A number of analysts have commented on the stock. Barclays PLC raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Argus reaffirmed a “buy” rating and set a $55.00 price target on shares of Sanofi in a research report on Friday, September 1st. Finally, raised shares of Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $53.50.
ILLEGAL ACTIVITY WARNING: This news story was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://theolympiareport.com/2017/11/21/next-financial-group-inc-sells-3936-shares-of-sanofi-sny.html.
Sanofi (SNY) traded down $0.22 during mid-day trading on Tuesday, hitting $44.32. 613,700 shares of the stock were exchanged, compared to its average volume of 1,516,191. The company has a market cap of $112,190.00, a PE ratio of 14.05, a PEG ratio of 2.46 and a beta of 0.88. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. Sanofi has a one year low of $38.45 and a one year high of $50.65.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.